Vivus ED drug succeeds in PhIII; Otsuka raising $2.4B;

> Shares of Vivus nudged up on the news that its erectile dysfunction drug avanafil had successfully finished a Phase III study. The developer, best known for its lead obesity drug, says it plans to file for an FDA approval in the second quarter of 2011. Story

> Japan's Otsuka has priced its IPO with an eye toward raising $2.4 billion. Much of that money is expected to be reserved to acquire new drug businesses. Report

> Roche says that a mid-stage study of its schizophrenia drug--RG1678--in combination with antipsychotics produced encouraging data. Another mid-stage study of a blood cancer drug also proved promising. Report

> Shares of Columbia Laboratories soared 37 percent on the news that its vaginal progesterone gel treatment aced a Phase III study, setting up a regulatory filing in the second quarter of next year. Article

> H. Lundbeck reports that the Phase III trial of clobazam for treating seizures linked to Lennox-Gastaut syndrome proved promising. Report

> NovaBay and Galderma are expanding their collaboration. Galderma has agreed to exercise its option to advance the clinical development program and will pay a $3.25 million continuation fee together with additional R&D funding in 2010 and 2011. NovaBay has the potential to receive up to $62 million in milestones from Galderma, and escalating double-digit royalties on net sales of products once commercialized. NovaBay release

And Finally... The season in which babies are born can have a dramatic and persistent effect on how their biological clocks function. Release

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.